Cytotoxic effect of different statins and thiazolidinediones on malignant glioma cells | Zendy

Jorge Humberto Tapia-Pérez | Zendy; Elmar Kirches | Zendy; Christian Mawrin | Zendy; Raimund Firsching | Zendy; Thomas Schneider | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Cytotoxic effect of different statins and thiazolidinediones on malignant glioma cells

Author(s) -

Jorge Humberto Tapia-Pérez,

Elmar Kirches,

Christian Mawrin,

Raimund Firsching,

Thomas Schneider

Publication year - 2010

Publication title -

cancer chemotherapy and pharmacology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.112

H-Index - 111

eISSN - 1432-0843

pISSN - 0344-5704

DOI - 10.1007/s00280-010-1535-2

Subject(s) - atorvastatin , lovastatin , rosiglitazone , pioglitazone , pharmacology , cytotoxic t cell , rosuvastatin , pravastatin , statin , simvastatin , fluvastatin , cytotoxicity , metformin , hmg coa reductase , gemfibrozil , medicine , chemistry , endocrinology , cholesterol , insulin , in vitro , diabetes mellitus , type 2 diabetes , reductase , biochemistry , enzyme

Glioblastoma multiforme is still a tumor with very poor prognosis. Statins are actually used for the treatment of dyslipidemias and thiazolidinediones for improving insulin sensitivity in diabetes. Statins are inhibitors of the cholesterol pathway, while thiazolidinediones are peroxisomal proliferator activator receptor γ (PPAR) agonists. For both, a potent pro-apoptotic activity has been suggested.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research